New Facility to expand Kraig Labs’ Research and Production Programs

ANN ARBOR, Mich., – October 23, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced the Company successfully opened its new research and production headquarters, designed to significantly enhance domestic production of spider silk based fibers and centralize the Company’s research and development program for new polymers, in Michigan.

The Company relocated its production operations from Indiana into its new larger headquarters.  Hatching and rearing of silkworms at the new facility has already begun, with three separate strains.  Over the next sixty days, the Company plans to expand the new facility’s production.  

Kraig Labs is, concurrently, in the process of hiring personnel, in the field of molecular biology, to accelerate the work in engineering exciting new polymers.  Individuals with strong laboratory experience working in genetic engineering, and interested in taking a lead role in a fast paced, growing biotechnology company, are encouraged to apply, Click Here.

“It was only earlier this month we announced our plan for the new research and production center,” said Company founder and CEO, Kim K Thompson.  “Less than thirty days later the new facility is already up and running, which is a testament to our dedicated employees, who made the transition to our larger new headquarters as seamless and as efficiently as we had hoped.  We especially want to thank those who relocated to Michigan to make this next stage in our growth possible.  This facility will be dedicated to fulfilling our contract with the Army, moving our product line to commercialization, as well as developing exciting new fibers and materials for unique applications”

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Company seen as nearing final clearance to begin hybridization in Vietnam

ANN ARBOR, Mich., -October 17, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that Company management has recently returned from a series of highly productive meetings with high level provincial and central government officials in Vietnam.  During these meetings the Company received the support and verbal approval to import the Company’s hybrid silkworms and begin selective breeding. This is the critical step in advancing the Company’s plans for commercial production in South East Asia.

During this trip, the Company’s management also met with its local architecture firm to review the master build plan for its proposed production site on 50 hectares.  Management also toured an existing facility which has been selected as the probable headquarters for its hybridization operations and early stage production. 

The Company is now working with officials from the Province as well as the Ministry to formalize the approvals granted during the meeting in Ha Noi. “To the best of our knowledge, clearance from one additional governmental unit is the only remaining regulatory hurdle to advancing the Company’s plans for selective breeding in Vietnam,” said COO Jon Rice.  The Company is now working with its consultants in Vietnam to expedite final clearance and to answer any additional questions or comments from the relevant Ministry.

“Obtaining this approval has been a lengthy process involving years of work in collecting data and conducting numerous meetings sharing that data with governmental agencies,” said CEO and Founder Kim Thompson. “The focus of those meetings has been answering their questions about our technology and how it can benefit the people and economy.  We believe that the most significant bureaucratic and regulatory hurdles are now behind us. We want to thank the governmental officials and other relevant parties who worked hard during this lengthy preparation and deliberative process.  We would also like to thank our loyal shareholders who have been navigating this lengthy regulatory process with us.  Without their support, none of our achievements would be possible.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,”

“foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Labs to expand its Research Team to support Domestic and International efforts

ANN ARBOR, Mich., – October 2, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced the Company is opening its new research and production headquarters in Michigan.  This facility will unite the Company’s ongoing recombinant spider silk production operations with its accelerating research into the creation of ever more powerful spider silk protein technologies. 

 Over the next 30 days, the Company will be relocating its current production operations, from Indiana into its new larger facility, and will transfer key production staff, to ensure continuity of operations.  This new facility offers better environmental control, roughly three times the production space, significantly reduces overhead costs, and, for the first time in the Company’s history, will allow the Company’s research and production teams to work side by side producing today’s spider silk based products, and creating tomorrow’s possibilities.

The Company created two new lead positions within its research group to support the new facility and growing research efforts.  Individuals with strong laboratory experience working in genetic engineered, and interested in taking a lead role in a fast paced, growing Biotechnology Company, are encouraged to apply, Click Here.

“Launching this new larger factory unifies our production and research teams’ efforts.  Having our teams working hand in hand will make us more agile and open up opportunities to move technologies more quickly from the drawing board to tested and validated designs,” said COO Jon Rice.    “In addition to streamlining developmental timelines and enhancing our ability to tailor fibers, we expect to reduce R&D costs, as we generate new spider silk technologies by fully integrating design, creation, testing, and scale up, under a single roof.  Our plan is to have this facility be the global central hub for spider silk technology and the center of our international operations.”

The Company’s domestic operations complement its ongoing work establishing international production centers.  Company management is currently considering three overseas locations for production.  Management is scheduled for meeting with senior central government officials in Hanoi, Vietnam in early October and is in ongoing discussions with another country silk producing country which has expressed interest in working with the Company to scale its spider silk technology.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.kraiglabs.com/newsletter

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Recent events position Kraig Labs with financial continuity and ability to focus on the Company’s Strategic Priorities

ANN ARBOR, Mich., -September 08, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company will not renew the equity line with Calm Seas Capital, which expired in June of 2017. 

The Company has maintained a financial relationship with Calm Seas Capital since before the creation of its first transgenic silkworm in 2010.  After careful consideration of its plan for commercialization and expansion, and after reviewing potential alternatives for financing that expansion, the Company’s management has determined it has outgrown the financial relationship. 

In addition to the recently extended U.S. Army contract, the Company implemented several strategic efficiency measures to reduce the Company’s fixed expenses.

“We value Calm Seas Capital’s contributions to many of our accomplishments, including the creation of new transgenics and recombinant fibers, however, given our projections for growth, this is the ideal time to transition for our business model’s next chapters,” said CEO and Founder, Kim Thompson.  “As the Company has grown, and, in light of our plans for future expansion and the Army’s recent exercise of its contract option with us for spider silk, it is timely for the Company to explore other avenues that are better aligned with our long term goals.  We’ve now grown to the point where we believe we have alternative financing options not previously available.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter    

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,”

“foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., -August 22, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB)

(“Company”), the leading developer of spider silk based fibers, today announced that the Company delivered the first Dragon Silk fibers to a medical equipment firm for performance and application suitability testing.

The Company is dedicating its current Dragon Silk production to fulfilling its recently exercised U.S. Army contract, but in recognition of the abundant sample requests that the Company received and due to this healthcare firm’s extensive expertise in medical technology development and innovation, the Company decided to supply a small amount of fibers, to be tested for strength, elasticity, and other properties. 

“It seems like we learn about amazing new potential spider silk medical breakthroughs on a near weekly basis, so we believe that medical technologies will be a very important space for Kraig’s future,” said CEO and Founder Kim Thompson.  “As the promise of our fibers becomes increasingly evident, the tests will allow engineers and product designers to understand our fibers’ unique properties, work to define specific opportunities, and accelerate future fiber innovation.”

“It’s important to note that much of this research is for a commonplace application and it’s in very early stages, yet we hope that the tests help in guiding us in building the blueprint for future fiber designs,” stated Jon Rice, COO.  “Based upon the initial evaluation of the fibers we are already working to modify the properties of the finished threads for these applications.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,”

“foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., -August 2, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the U.S. Army awarded the optional phase of its contract with the Company valued at more than $900,000.  Under this exercised option, the Company will work to design, produce, and deliver additional recombinant spider silk materials tailored for the protective needs of our Soldiers.  With this additional award the total contract is now valued at more than $1.0 million. 

“When I founded this Company it was with the dream that one day we would work with the US Army to produce ultra-high strength materials in support of our Warfighters,” said Company CEO and founder, Kim K. Thomson.  “The Army’s exercise of its option under our agreement validates that dream.  Our team is honored to be working on this noble project and we intend to provide this very important customer with the very best high strength polymers using our recombinant spider silk technology.”

“We are extremely excited to continue our work with the US Army to deliver revolutionary materials to support the Warfighter,” stated Jon Rice, COO.  “Under this new phase we will be working closely with our sponsor agency to match the performance of our spider silk to their specific use cases and protective applications.  I would like to thank our team for the incredible amount of effort they’ve put in to make the first phase of this project a success and express my gratitude to our sponsor for the trust and confidence they’ve placed in us to deliver the next generation of spider silk solutions.   The potential uses of spider silk are nearly limitless, but one of the greatest honors is being able to apply our technology to serving those who dedicate themselves to serving and protecting all of us.”

This additional work on the contract is scheduled to last roughly 12 months and is the Company’s second US Department of Defense award.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,”

“foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – July 24 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that it has identified and selected the location for its operational headquarters in Vietnam.  Located in the heart of Quang Nam province, this area provides a vast supply of skilled workers, close proximity to mulberry fields, and easy access to international air and sea ports.  This location was selected based on a series of productive and successful meetings between representatives of Kraig Labs, provincial leaders, and local silk experts.  The Company plans for this facility to be used for the first shipment of the Company’s transgenic silkworm technology into Vietnam. 

“Identifying our corporate headquarters was an essential part of our application to import our silkworm into Vietnam,” Said COO Jon Rice.  “With this location finalized we are now preparing the final importation documents for submission in order to obtain approvals to begin work with our hybrid silk technology in Vietnam.”

In addition to progress made in securing a new Vietnamese headquarters the Company has also been working with local experts to prepare a master plan for the 50 hectares dedicated to this project.  The Company expects to review those plans in the coming weeks.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com